欧洲紫杉烷市场，按类型（紫杉醇、多西他赛、卡巴他赛）、药物类型（仿制药、品牌药）、剂型（脂质体、纳米颗粒、聚合物胶束、其他）、年龄组（成人、老年人）、应用（乳腺癌、非小细胞肺癌、胰腺癌、卵巢癌、前列腺癌、其他）、最终用户（医院、门诊手术中心、专科诊所、其他）分销渠道（零售、直接招标）划分 - 行业趋势和预测到 2029 年。
市场分析和见解
预计欧洲紫杉烷市场将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场的复合年增长率为 7.1%。紫杉烷药物治疗的技术进步，加上计算机辅助诊断的应用日益增多，是推动预测期内紫杉烷市场增长的其他因素。
然而，药物的高成本以及血栓、白细胞减少、过敏、腹泻和体重减轻等副作用将抑制市场的增长。主要市场参与者建立合作伙伴关系和收购等战略联盟是紫杉烷市场增长的机会。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020 |
|
定量单位 |
收入（百万美元），定价（美元） |
|
涵盖的领域 |
按类型（紫杉醇、多西他赛和卡巴他赛）、药品类型（品牌药和仿制药）、剂型（含紫杉烷的脂质体和聚合物胶束、紫杉烷的水凝胶剂型、纳米颗粒剂型等）、年龄组（成人和老年人）、应用（卵巢癌、乳腺癌、前列腺癌、非小细胞肺癌等）、最终用户（医院、门诊手术中心、专科诊所等）、分销渠道（直接招标、零售） |
|
覆盖国家 |
德国、法国、英国、意大利、西班牙、俄罗斯、西班牙、土耳其、比利时、荷兰、瑞士、波兰、奥地利、匈牙利、立陶宛、挪威、爱尔兰和欧洲其他国家 |
|
涵盖的市场参与者 |
Viatris Inc.、Sandoz International GmbH（诺华公司旗下的一个部门）、sanofi-aventis US LLC、Hikma Pharmaceuticals PLC、辉瑞公司、Dr. Reddy's Laboratories Ltd.、Taxane Healthcare、百时美施贵宝公司、Fresenius Kabi AG（Fresenius SE & Co. KGaA 的子公司）、三阳控股株式会社、绿叶制药集团、Elevar Therapeutics、辉昂药业股份有限公司、深圳万乐药业有限公司、Accord Healthcare、Torrent Pharmaceuticals Ltd.、Panacea Biotec、RPG Life Sciences Limited.、Aureate Healthcare、Samarth Life Sciences Pvt. Ltd.、Cipla Inc.、Hetero Healthcare Limited.、AqVida GmbH、Ingenus Pharmaceuticals, LLC 等等。 |
紫杉烷市场定义
紫杉烷或紫杉醇类是一类密切相关的抗肿瘤药物，具有作为有丝分裂抑制剂的独特作用机制，广泛用于治疗卵巢癌、乳腺癌、肺癌、食道癌、前列腺癌、膀胱癌和头颈癌。临床上使用的紫杉烷有三种，即紫杉醇 (Taxol：1992 年)、多西他赛 (Taxotere：1996 年) 和卡巴他赛 (Jevtana：2010 年)。紫杉烷是干扰微管功能，导致有丝分裂改变和细胞死亡的抗癌药物。紫杉醇 (Taxol) 最早是从紫杉树中分离出来的，紫杉树是一种生长速度缓慢的小型常绿针叶树。由于紫杉醇最初很稀缺，因此人们从欧洲紫杉树 Taxus baccata 的针叶中提取了紫杉醇的半合成类似物多西他赛 (Taxotere)。多西他赛与紫杉醇在两个化学位置上有所不同，这使得它更易溶于水。卡巴他赛也是天然紫杉醇的半合成类似物，因其对 P-糖蛋白（多西他赛耐药性的常见介质）缺乏亲和力而被开发出来。
此外，由于慢性病发病率上升、癌症发病率飙升以及医疗基础设施投资增加，紫杉烷类药物的使用量不断增加。这些因素增加了紫杉烷类市场的需求，并鼓励主要市场参与者通过产品发布、收购、战略和协议来实施新技术和战略。
紫杉烷市场动态
驱动程序
- 癌症发病率上升
癌症对美国和全世界的社会产生了重大影响。癌症统计数据描述了大群体中发生的情况，并及时描绘出癌症对社会造成的负担。紫杉醇是一种用于治疗癌症的抗有丝分裂剂，它通过阻止细胞分裂来阻止癌细胞生长，从而导致细胞死亡。
据美国国家癌症研究所 (NCI) 称，一项由政府资助的临床试验发现，30% 的晚期卵巢癌患者对紫杉烷治疗反应良好。在临床实践中，紫杉烷现在是转移性乳腺癌的标准疗法。如今，紫杉醇已被列入世界卫生组织的基本药物标准清单，是一种可以杀死癌细胞的细胞毒性药物。它可以治疗乳腺癌、卵巢癌、非小细胞肺癌、胰腺癌和艾滋病相关的卡波西肉瘤。
- 政府的资助和研发的投资
尽管药物疗法在治疗阿片类药物滥用和酒精成瘾方面已得到证实，但人们发现，紫杉烷在专科治疗计划中的应用存在局限性。需要特别注意资金、组织结构和人力资源的具体来源，进行长期投资，使资金支付与未来的潜在受益者保持一致。药物开发的可持续性、生产力和患者影响问题从来都不是、也不会仅仅是行业的产物。
政府的资助将确保患者的安全，节省医疗费用。此外，医院和医疗机构将通过与政府机构合作，以较低的价格实施这种治疗。因此，研发活动的进步和政府的资助预计将推动市场增长。
克制
- 紫杉烷类药物的副作用
紫杉烷属于二萜类。紫杉烷类药物（紫杉醇和多西他赛）用作化疗药物。由于正在进行的临床试验、研究、癌症类型、治疗方案类型和药物剂量，目前的高成本预计未来将呈下降趋势。紫杉烷类药物对治疗乳腺癌和前列腺癌最有效。然而，已报告某些副作用。报告的不良并发症或副作用将导致紫杉烷类药物销量下降，从而限制药物的销量。此外，它还会影响参与该市场的制造商的可靠性，因此预计会抑制市场增长。
机会
-
市场参与者的战略主动性
由于及时治疗酒精和阿片类药物障碍，美国和欧洲对紫杉烷市场的需求有所增加。这些有利因素增加了对紫杉烷的需求，为了满足市场需求，大大小小的市场参与者都在采用各种策略。
主要参与者还试图制定具体的策略，例如产品发布、收购、批准、扩张和合作，以确保业务顺利进行，避免风险，并增加市场销售的长期增长。
市场参与者的这些战略举措，包括收购、会议和重点细分产品发布，正在帮助公司发展并改善公司的产品组合，最终带来更多收入。因此，市场参与者的这些战略举措为未来增长和推动市场增长提供了机会。
挑战
- 缺乏紫杉类药物治疗所需的熟练专业人员
缺乏或短缺专业技能将影响一个地方的复苏和增长速度。一个地方的失业者往往拥有其他地方所缺乏的技能。此外，该领域的快速技术进步也导致缺乏专业知识。
医生供应量是一个术语，用于描述在医疗保健系统或劳动力市场中工作的受过培训的医生的数量。它取决于毕业生的数量和该专业的留任率。医生短缺是全球许多国家日益关注的问题。
世界卫生组织 (WHO) 估计，全球医生、护士和其他卫生专业人员的缺口为 430 万。尽管有强有力的证据表明药物在降低发病率和死亡率、增加治疗保留率和改善紫杉烷类药物患者健康状况方面有效，但众多障碍阻碍了更广泛地获得紫杉烷类药物治疗。
此外，技术进步是导致对熟练专业人员需求增加的另一个方面。神经科医生报告称，他们的中心存在大量未满足的支持性护理需求和障碍，只有少数人认为自己有能力提供支持性护理。迫切需要对治疗痴呆症的专业人员进行教育，并采购可用的支持性护理资源。缺乏训练有素且经验丰富的专业人员以及持续存在的技能差距限制了就业前景和获得优质工作的机会。因此，显然，拥有足够技能的专业人员的可用性对市场增长构成了挑战。
COVID-19 对紫杉烷市场的影响
COVID-19 导致医护人员和普通民众对医疗用品的需求大幅增加，以采取预防措施。这些产品的制造商有机会通过确保市场上个人防护设备的稳定供应来利用医疗用品需求的增长。预计 COVID-19 将对紫杉烷市场产生重大影响。
最新动态
- 2022 年 11 月，Viatris Inc. 和 Biocon Biologics Ltd. 宣布在美国推出可互换的生物仿制药 SEMGLEE（甘精胰岛素-yfgn）注射液（品牌产品）和 Insulin Glargine（甘精胰岛素-yfgn）注射液（无品牌产品），以帮助控制成人和儿童 1 型糖尿病患者以及成人 2 型糖尿病患者的高血糖。这两种生物仿制药均有小瓶和预充笔形式，可与参考品牌 LANTUS（甘精胰岛素）互换，从而可以在药房柜台进行替换。Viatris 致力于改善患者获得可持续、优质和更实惠的医疗保健的机会。这有助于公司扩大其产品组合。
- 2022 年 5 月，仿制药和生物类似药领域的全球领导者 Sandoz 宣布在美国推出其仿制药吡非尼酮，这是首个与 Genentech 的 Esbriet 相当的 AB 级（完全可替代）药物，用于治疗特发性肺纤维化 (IPF) 患者。这种处方口服药可通过专科药房立即提供给患者，符合条件的患者可享受 0 美元自付费用计划。Sandoz 将患者放在首位，扩大了这种罕见疾病患者获得仿制药吡非尼酮的机会，他们将受益于更实惠但同样有效的治疗。这有助于该公司扩大其市场地位和业务。
紫杉烷的应用范围和市场规模
紫杉烷市场根据类型、药物类型、配方、年龄组、应用、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
按类型
- 紫杉醇
- 多西他赛
- 卡巴他赛
根据类型，欧洲紫杉烷市场分为紫杉醇、多西他赛和卡巴他赛。
按应用
- 卵巢癌
- 乳腺癌
- 前列腺癌
- 非小细胞肺癌
- 其他
根据应用，欧洲紫杉烷市场分为卵巢癌、乳腺癌、前列腺癌、非小细胞肺癌和其他。
按药物类型
- 泛型
- 品牌
根据药物类型，欧洲紫杉烷市场分为品牌药物和仿制药。
按配方
- 脂质体
- 纳米粒子
- 聚合物胶束
- 其他的
根据配方，欧洲紫杉烷市场分为脂质体、纳米颗粒、聚合物胶束和其他。
按年龄组
- 成人
- 老年
根据年龄组，欧洲紫杉烷市场分为成年人和老年人。
按最终用户
- 医院
- 门诊手术中心
- 专科诊所
- 其他的
根据最终用户，欧洲紫杉烷市场分为医院、门诊手术中心、专科诊所和其他。
按分销渠道
- 直接招标
- 零售销售
根据分销渠道，欧洲紫杉烷市场分为直接招标、零售。
欧洲紫杉烷市场区域分析
对紫杉烷市场进行分析，并按类型、药物类型、配方、年龄组、应用、最终用户和分销渠道提供市场规模信息。
紫杉烷市场报告涉及的国家包括德国、法国、英国、意大利、西班牙、俄罗斯、西班牙、土耳其、比利时、荷兰、瑞士、波兰、奥地利、匈牙利、立陶宛、挪威、爱尔兰和欧洲其他国家。
2022 年，德国占据主导地位，因为其拥有主要市场参与者以及最大的 GDP 较高的消费市场。由于药物治疗技术的进步，德国预计将实现增长。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
紫杉烷市场还为您提供每个国家医疗保健行业增长的详细市场分析。此外，它还提供有关医疗保健服务和治疗、监管情景的影响以及紫杉烷市场趋势参数的详细信息。
竞争格局和紫杉烷市场份额分析
紫杉烷市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对紫杉烷药物的关注有关。
在紫杉烷市场开展业务的主要公司有 Viatris Inc.、Sandoz International GmbH（诺华公司旗下的一个部门）、sanofi-aventis US LLC、Hikma Pharmaceuticals PLC、辉瑞公司、Dr. Reddy's Laboratories Ltd.、Taxane Healthcare、百时美施贵宝公司、Fresenius Kabi AG（Fresenius SE & Co. KGaA 的子公司）、SAMYANG HOLDINGS CORPORATION.、绿叶制药集团、Elevar Therapeutics、辉昂药业股份有限公司、深圳万乐药业有限公司、Accord Healthcare、Torrent Pharmaceuticals Ltd.、Panacea Biotec、RPG Life Sciences Limited.、Aureate Healthcare、Samarth Life Sciences Pvt. Ltd.、Cipla Inc.、Hetero Healthcare Limited.、AqVida GmbH、Ingenus Pharmaceuticals, LLC 等等。
预计主要市场参与者的合并、收购和协议等战略联盟将进一步加速紫杉烷药物的增长。
市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在紫杉烷市场的影响力，这也为组织的利润增长带来了好处。
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、亚太地区与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE TAXANE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL_ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
6.1 CONCLUSION
7 EUROPE TAXANE MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 THE RISE IN INCIDENCE OF CANCER
8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT
8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS
8.1.4 USE OF REIMBURSEMENT FOR TAXANE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS
8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT
8.2.3 RISE IN PRODUCT RECALLS
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT
8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT
9 EUROPE TAXANE MARKET, BY TYPE
9.1 OVERVIEW
9.2 PACLITAXEL
9.2.1 BY TYPE
9.2.1.1 SEMI-SYNTHETIC
9.2.1.2 NATURAL
9.2.2 BY STRENGTH
9.2.2.1 100MG
9.2.2.2 200MG
9.2.2.3 250MG
9.2.2.4 30MG
9.2.2.5 260MG
9.2.2.6 300MG
9.3 DOCETAXEL
9.3.1 120MG
9.3.2 80MG
9.3.3 20MG
9.3.4 40MG
9.3.5 60MG
9.4 CABAZITAXEL
9.4.1 60MG
10 EUROPE TAXANE MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 BREAST CANCER
10.3 NON-SMALL CELL LUNG CANCER
10.4 PANCREATIC CANCER
10.5 OVARIAN CANCER
10.6 PROSTATE CANCER
10.7 OTHERS
11 EUROPE TAXANE MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 GENERICS
11.3 BRANDED
12 EUROPE TAXANE MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 LIPOSOMES
12.3 NANOPARTICLES
12.4 POLYMERIC MICELLES
12.5 OTHERS
13 EUROPE TAXANE MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.2.1 FEMALE
13.2.2 MALE
13.3 GERIATRIC
13.3.1 FEMALE
13.3.2 MALE
14 EUROPE TAXANE MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 AMBULATORY SURGICAL CENTERS
14.4 SPECIALTY CLINICS
14.5 OTHERS
15 EUROPE TAXANE MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 HOSPITAL PHARMACY
15.2.2 RETAIL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
16 EUROPE TAXANE MARKET, BY REGION
16.1 EUROPE
16.1.1 GERMANY
16.1.2 FRANCE
16.1.3 U.K.
16.1.4 ITALY
16.1.5 RUSSIA
16.1.6 SPAIN
16.1.7 TURKEY
16.1.8 NETHERLANDS
16.1.9 SWITZERLAND
16.1.10 POLAND
16.1.11 BELGIUM
16.1.12 HUNGARY
16.1.13 AUSTRIA
16.1.14 NORWAY
16.1.15 IRELAND
16.1.16 LITHUANIA
16.1.17 REST OF EUROPE
17 EUROPE TAXANE MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: EUROPE
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 BRISTOL-MYERS SQUIBB COMPANY
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 SANOFI-AVENTIS U.S. LLC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA )
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 HIKMA PHARMACEUTICALS PLC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 ACCORD HEALTHCARE
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 AQVIDA GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 AUREATE HEALTHCARE
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 DR. REDDY’S LABORATORIES LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 ELEVAR THERAPEUTICS
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENTS
19.13 HETERO HEALTHCARE LIMITED.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 HUIANG PHARMACEUTICAL CO LTD
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 INGENUS PHARMACEUTICALS, LLC
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 LUYE PHARMA GROUP
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 PANACEA BIOTEC
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 RPG LIFE SCIENCES LIMITED
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SAMARTH LIFE SCIENCES PVT. LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 SAMYANG HOLDINGS CORPORATION.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 TORRENT PHARMACEUTICALS LTD
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 TAXANE HEALTHCARE
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 EUROPE TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE PACLITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 EUROPE PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 5 EUROPE DOCETAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 7 EUROPE CABAZITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 9 EUROPE TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE BREAST CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE NON-SMALL LUNG CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE PANCREATIC CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE OVARIAN CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE PROSTATE CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE GENERICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE BRANDED IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE LIPOSOMES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE NANOPARTICLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE POLYMERIC MICELLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 25 EUROPE ADULT IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 27 EUROPE GERIATRIC IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 29 EUROPE TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 EUROPE HOSPITALS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE AMBULATORY SURGICAL CENTERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE SPECIALTY CLINICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 EUROPE RETAIL SALES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 37 EUROPE DIRECT TENDER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE TAXANE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 EUROPE TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 EUROPE PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 EUROPE TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 EUROPE TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 43 EUROPE TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 44 EUROPE PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 45 EUROPE DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 46 EUROPE CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 47 EUROPE TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 48 EUROPE ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 49 EUROPE GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 50 EUROPE TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 EUROPE TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 EUROPE RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 GERMANY TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 GERMANY PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 GERMANY TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 GERMANY TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 57 GERMANY TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 GERMANY PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 59 GERMANY DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 60 GERMANY CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 61 GERMANY TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 62 GERMANY ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 63 GERMANY GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 64 GERMANY TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 GERMANY TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 GERMANY RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 FRANCE TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 FRANCE PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 FRANCE TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 FRANCE TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 71 FRANCE TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 72 FRANCE PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 73 FRANCE DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 74 FRANCE CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 75 FRANCE TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 76 FRANCE ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 77 FRANCE GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 78 FRANCE TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 FRANCE TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 80 FRANCE RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 81 U.K. TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 U.K. PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 U.K. TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 U.K. TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 85 U.K. TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 86 U.K. PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 87 U.K. DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 88 U.K. CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 89 U.K. TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 90 U.K. ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 91 U.K. GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 92 U.K. TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 U.K. TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 U.K. RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 ITALY TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 ITALY PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 ITALY TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 98 ITALY TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 99 ITALY TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 100 ITALY PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 101 ITALY DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 102 ITALY CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 103 ITALY TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 104 ITALY ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 105 ITALY GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 106 ITALY TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 107 ITALY TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 108 ITALY RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 109 RUSSIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 RUSSIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 RUSSIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 112 RUSSIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 113 RUSSIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 114 RUSSIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 115 RUSSIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 116 RUSSIA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 117 RUSSIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 118 RUSSIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 119 RUSSIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 120 RUSSIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 121 RUSSIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 122 RUSSIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 SPAIN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 SPAIN PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 SPAIN TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 126 SPAIN TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 127 SPAIN TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 128 SPAIN PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 129 SPAIN DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 130 SPAIN CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 131 SPAIN TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 132 SPAIN ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 133 SPAIN GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 134 SPAIN TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 135 SPAIN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 136 SPAIN RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 137 TURKEY TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 TURKEY PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 TURKEY TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 140 TURKEY TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 141 TURKEY TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 142 TURKEY PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 143 TURKEY DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 144 TURKEY CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 145 TURKEY TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 146 TURKEY ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 147 TURKEY GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 148 TURKEY TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 149 TURKEY TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 150 TURKEY RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 151 NETHERLANDS TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 NETHERLANDS PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 NETHERLANDS TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 154 NETHERLANDS TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 155 NETHERLANDS TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 156 NETHERLANDS PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 157 NETHERLANDS DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 158 NETHERLANDS CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 159 NETHERLANDS TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 160 NETHERLANDS ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 161 NETHERLANDS GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 162 NETHERLANDS TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 163 NETHERLANDS TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 164 NETHERLANDS RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 165 SWITZERLAND TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 SWITZERLAND PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 SWITZERLAND TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 168 SWITZERLAND TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 169 SWITZERLAND TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 170 SWITZERLAND PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 171 SWITZERLAND DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 172 SWITZERLAND CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 173 SWITZERLAND TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 174 SWITZERLAND ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 175 SWITZERLAND GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 176 SWITZERLAND TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 177 SWITZERLAND TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 178 SWITZERLAND RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 179 POLAND TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 POLAND PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 POLAND TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 182 POLAND TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 183 POLAND TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 184 POLAND PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 185 POLAND DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 186 POLAND CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 187 POLAND TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 188 POLAND ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 189 POLAND GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 190 POLAND TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 191 POLAND TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 192 POLAND RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 193 BELGIUM TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 BELGIUM PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 BELGIUM TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 196 BELGIUM TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 197 BELGIUM TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 198 BELGIUM PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 199 BELGIUM DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 200 BELGIUM CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 201 BELGIUM TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 202 BELGIUM ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 203 BELGIUM GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 204 BELGIUM TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 205 BELGIUM TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 206 BELGIUM RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 207 HUNGARY TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 HUNGARY PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 209 HUNGARY TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 210 HUNGARY TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 211 HUNGARY TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 212 HUNGARY PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 213 HUNGARY DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 214 HUNGARY CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 215 HUNGARY TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 216 HUNGARY ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 217 HUNGARY GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 218 HUNGARY TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 219 HUNGARY TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 220 HUNGARY RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 221 AUSTRIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 AUSTRIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 AUSTRIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 224 AUSTRIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 225 AUSTRIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 226 AUSTRIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 227 AUSTRIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 228 AUSTRIA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 229 AUSTRIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 230 AUSTRIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 231 AUSTRIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 232 AUSTRIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 233 AUSTRIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 234 AUSTRIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 235 NORWAY TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 NORWAY PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 NORWAY TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 238 NORWAY TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 239 NORWAY TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 240 NORWAY PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 241 NORWAY DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 242 NORWAY CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 243 NORWAY TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 244 NORWAY ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 245 NORWAY GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 246 NORWAY TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 247 NORWAY TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 248 NORWAY RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 249 IRELAND TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 250 IRELAND PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 251 IRELAND TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 252 IRELAND TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 253 IRELAND TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 254 IRELAND PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 255 IRELAND DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 256 IRELAND CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 257 IRELAND TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 258 IRELAND ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 259 IRELAND GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 260 IRELAND TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 261 IRELAND TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 262 IRELAND RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 263 LITHUANIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 264 LITHUANIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 265 LITHUANIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 266 LITHUANIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 267 LITHUANIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 268 LITHUANIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 269 LITHUANIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 270 LITHUANIA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 271 LITHUANIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 272 LITHUANIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 273 LITHUANIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 274 LITHUANIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 275 LITHUANIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 276 LITHUANIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 277 REST OF EUROPE TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 EUROPE TAXANE MARKET: SEGMENTATION
FIGURE 2 EUROPE TAXANE MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE TAXANE MARKET: DROC ANALYSIS
FIGURE 4 EUROPE TAXANE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE TAXANE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE TAXANE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE TAXANE MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE TAXANE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE TAXANE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE TAXANE MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE EUROPE TAXANE MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INVESTMENT FOR HEALTHCARE INFRASTRUCTURE IS EXPECTED TO DRIVE THE EUROPE TAXANE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE TAXANE MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE TAXANE MARKET
FIGURE 15 INCIDENCE OF BREAST CANCER IN 2020
FIGURE 16 EUROPE TAXANE MARKET: BY TYPE, 2021
FIGURE 17 EUROPE TAXANE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 EUROPE TAXANE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE TAXANE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 EUROPE TAXANE MARKET: BY APPLICATION, 2021
FIGURE 21 EUROPE TAXANE MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 22 EUROPE TAXANE MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 23 EUROPE TAXANE MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 EUROPE TAXANE MARKET: BY DRUG TYPE, 2021
FIGURE 25 EUROPE TAXANE MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 26 EUROPE TAXANE MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 27 EUROPE TAXANE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 EUROPE TAXANE MARKET: BY FORMULATION, 2021
FIGURE 29 EUROPE TAXANE MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 EUROPE TAXANE MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 EUROPE TAXANE MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 EUROPE TAXANE MARKET: BY AGE GROUP, 2021
FIGURE 33 EUROPE TAXANE MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 34 EUROPE TAXANE MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 35 EUROPE TAXANE MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 36 EUROPE TAXANE MARKET: BY END USER, 2021
FIGURE 37 EUROPE TAXANE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 38 EUROPE TAXANE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 EUROPE TAXANE MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 EUROPE TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 EUROPE TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 42 EUROPE TAXANE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 EUROPE TAXANE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 EUROPE TAXANE MARKET: SNAPSHOT (2021)
FIGURE 45 EUROPE TAXANE MARKET: BY COUNTRY (2021)
FIGURE 46 EUROPE TAXANE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 EUROPE TAXANE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 EUROPE TAXANE MARKET: BY TYPE (2022-2029)
FIGURE 49 EUROPE TAXANE MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
